Published in J Leukoc Biol on May 21, 2008
Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells. J Infect Dis (2012) 1.70
Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS (2009) 1.05
Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection. PLoS Pathog (2015) 1.02
Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: mechanisms, impacts and therapeutic implications. Cell Mol Immunol (2012) 0.96
Impact of age, gender, and race on circulating γδ T cells. Hum Immunol (2010) 0.92
Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro. Cancer Immunol Immunother (2010) 0.92
CD8 T cells and Mycobacterium tuberculosis infection. Semin Immunopathol (2015) 0.91
The γδ T-cell receptor repertoire is reconstituted in HIV patients after prolonged antiretroviral therapy. AIDS (2013) 0.83
Levels of CD56+TIM-3- effector CD8 T cells distinguish HIV natural virus suppressors from patients receiving antiretroviral therapy. PLoS One (2014) 0.82
Impairment of CD1d-restricted natural killer T cells in chronic HIV type 1 clade C infection. AIDS Res Hum Retroviruses (2010) 0.82
HIV-1-induced impairment of dendritic cell cross talk with γδ T lymphocytes. J Virol (2015) 0.76
Inhibition of R5-tropic HIV type-1 replication in CD4⁺ natural killer T cells by γδ T lymphocytes. Immunology (2014) 0.76
Spectrum of AIDS-associated malignant disorders. Lancet (1998) 5.30
[gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol (2000) 5.01
CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest (1995) 3.97
CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol (1994) 3.50
Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J Exp Med (1990) 3.38
Two forms of the T-cell receptor gamma protein found on peripheral blood cytotoxic T lymphocytes. Nature (1987) 3.37
AIDS-related cancer and severity of immunosuppression in persons with AIDS. J Natl Cancer Inst (2007) 3.28
Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med (1998) 3.24
Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol (2006) 2.45
Elevated risk of lung cancer among people with AIDS. AIDS (2007) 2.20
Selection by two powerful antigens may account for the presence of the major population of human peripheral gamma/delta T cells. J Exp Med (1991) 2.09
Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. J Exp Med (2003) 1.86
Selective loss of innate CD4(+) V alpha 24 natural killer T cells in human immunodeficiency virus infection. J Virol (2002) 1.74
T cell receptor gamma/delta+ lymphocyte subsets during HIV infection. Clin Exp Immunol (1989) 1.72
Peripheral V gamma 9/V delta 2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J Immunol (1996) 1.60
In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol (2005) 1.57
Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin Diagn Lab Immunol (2001) 1.54
Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. J Exp Med (1990) 1.50
Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J Immunol (2002) 1.46
V gamma 9V delta 2 T cell response to colon carcinoma cells. J Immunol (2005) 1.45
In vitro stimulation with a non-peptidic alkylphosphate expands cells expressing Vgamma2-Jgamma1.2/Vdelta2 T-cell receptors. Immunology (2001) 1.36
CD45: all is not yet crystal clear. Immunology (2006) 1.30
CD27 is a signal-transducing molecule involved in CD45RA+ naive T cell costimulation. J Immunol (1994) 1.28
Adaptive immune response of Vgamma2Vdelta2 T cells: a new paradigm. Trends Immunol (2003) 1.27
FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood (2004) 1.27
Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol (2002) 1.23
Functional gamma delta T-lymphocyte defect associated with human immunodeficiency virus infections. Mol Med (1997) 1.16
Granzyme B induces BID-mediated cytochrome c release and mitochondrial permeability transition. J Biol Chem (2000) 1.15
HIV-mediated gammadelta T cell depletion is specific for Vgamma2+ cells expressing the Jgamma1.2 segment. AIDS Res Hum Retroviruses (2003) 1.14
Human V gamma 2V delta 2 T cells produce IFN-gamma and TNF-alpha with an on/off/on cycling pattern in response to live bacterial products. J Immunol (2001) 1.14
Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells. J Leukoc Biol (2006) 1.08
Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens. Cancer Immunol Immunother (2006) 1.04
Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. Cytometry (1995) 0.99
Recognition of nonpeptide prenyl pyrophosphate antigens by human gammadelta T cells Microbes Infect (1999) 0.98
Vaccinia virus inhibits T cell receptor-dependent responses by human gammadelta T cells. J Infect Dis (2006) 0.97
Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vgamma9Vdelta2 T cells in chronically infected patients undergoing structured treatment interruption. J Infect Dis (2002) 0.97
Attenuated disease in SIV-infected macaques treated with a monoclonal antibody against FasL. Clin Dev Immunol (2007) 0.95
Gamma delta T cells in rhesus monkeys and their response to simian immunodeficiency virus (SIV) infection. Clin Exp Immunol (1995) 0.95
Synthetic phosphoantigens enhance human Vgamma9Vdelta2 T lymphocytes killing of non-Hodgkin's B lymphoma. Mol Med (2001) 0.92
Vdelta1 and Vdelta2 gammadelta T cells express distinct surface markers and might be developmentally distinct lineages. J Leukoc Biol (2001) 0.91
Macrophages express granzyme B in the lesion areas of atherosclerosis and rheumatoid arthritis. Immunol Lett (2007) 0.90
HIV Tat binds Egr proteins and enhances Egr-dependent transactivation of the Fas ligand promoter. J Biol Chem (2002) 0.88
Induction of the EBV cycle in B-lymphocyte-derived lines is accompanied by increased natural killer (NK) sensitivity and the expression of EBV-related antigen(s) detected by the ADCC reaction. Int J Cancer (1980) 0.85
Mucosal lymphatic-derived gammadelta T cells respond early to experimental Salmonella enterocolitis by increasing expression of IL-2R alpha. Cell Immunol (2007) 0.85
Kaposi's sarcoma in three HIV-1-infected cohorts. J Acquir Immune Defic Syndr (1990) 0.82
Requirement for CD4+ T cells in the gammadelta T cell proliferative response to Daudi Burkitt's lymphoma. Cell Immunol (1996) 0.80
Specificity and function of gamma delta T lymphocytes. Folia Biol (Praha) (1992) 0.80
Human immunodeficiency virus (HIV) gag antigen-specific T-helper and granule-dependent CD8 T-cell activities in exposed but uninfected heterosexual partners of HIV type 1-infected individuals in North India. Clin Vaccine Immunol (2007) 0.80
Anti-apoptotic seminal vesicle protein IV inhibits cell-mediated immunity. J Reprod Immunol (2008) 0.77
Human CD3 gamma delta + activated lymphocytes exhibit killer activity in vitro against autologous leukemic cells. Nouv Rev Fr Hematol (1989) 0.76
Association between Vgamma2Vdelta2 T cells and disease progression after infection with closely related strains of HIV in China. Clin Infect Dis (2008) 1.72
Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells. J Infect Dis (2012) 1.70
Lack of CD27-CD45RA-V gamma 9V delta 2+ T cell effectors in immunocompromised hosts and during active pulmonary tuberculosis. J Immunol (2002) 1.46
Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement. Blood (2010) 1.38
Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma. Clin Cancer Res (2008) 1.32
Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol (2003) 1.25
Early blood profiles of virus infection in a monkey model for Lassa fever. J Virol (2007) 1.20
HIV-mediated gammadelta T cell depletion is specific for Vgamma2+ cells expressing the Jgamma1.2 segment. AIDS Res Hum Retroviruses (2003) 1.14
Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire. J Infect Dis (2004) 1.10
Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine (2008) 1.09
Whole-body positron emission tomography in patients with HIV-1 infection. Lancet (2003) 1.07
A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol (2011) 1.06
Gamma interferon secretion by human Vgamma2Vdelta2 T cells after stimulation with antibody against the T-cell receptor plus the Toll-Like receptor 2 agonist Pam3Cys. Infect Immun (2006) 1.06
Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells. AIDS (2009) 1.05
Individual Vgamma2-Jgamma1.2+ T cells respond to both isopentenyl pyrophosphate and Daudi cell stimulation: generating tumor effectors with low molecular weight phosphoantigens. Cancer Immunol Immunother (2006) 1.04
Role of the Fas/FasL pathway in HIV or SIV disease. Retrovirology (2009) 1.02
Failure to restore the Vgamma2-Jgamma1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin Immunol (2008) 1.01
Control of CD56 expression and tumor cell cytotoxicity in human Vgamma2Vdelta2 T cells. BMC Immunol (2009) 1.00
Brucellosis in San Diego: epidemiology and species-related differences in acute clinical presentations. Medicine (Baltimore) (2005) 1.00
High cancer-related mortality in an urban, predominantly African-American, HIV-infected population. AIDS (2013) 0.99
HIV Tat protein increases Bcl-2 expression in monocytes which inhibits monocyte apoptosis induced by tumor necrosis factor-alpha-related apoptosis-induced ligand. Intervirology (2007) 0.97
Vaccinia virus inhibits T cell receptor-dependent responses by human gammadelta T cells. J Infect Dis (2006) 0.97
HIV envelope-mediated, CCR5/α4β7-dependent killing of CD4-negative γδ T cells which are lost during progression to AIDS. Blood (2011) 0.96
Depletion and dysfunction of Vγ2Vδ2 T cells in HIV disease: mechanisms, impacts and therapeutic implications. Cell Mol Immunol (2012) 0.96
Attenuated disease in SIV-infected macaques treated with a monoclonal antibody against FasL. Clin Dev Immunol (2007) 0.95
High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS One (2010) 0.95
Reference values of lymphocyte subsets in healthy, HIV-negative children in Cameroon. Clin Vaccine Immunol (2011) 0.94
Tat-neutralizing antibodies in vaccinated macaques. J Virol (2003) 0.94
TNF-alpha is a positive regulatory factor for human Vgamma2 Vdelta2 T cells. J Immunol (2008) 0.93
Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS (2007) 0.92
Impact of age, gender, and race on circulating γδ T cells. Hum Immunol (2010) 0.92
Rapamycin increases the yield and effector function of human γδ T cells stimulated in vitro. Cancer Immunol Immunother (2010) 0.92
Globalization, climate change, and human health. N Engl J Med (2013) 0.92
The proline-rich homeodomain (PRH/HEX) protein is down-regulated in liver during infection with lymphocytic choriomeningitis virus. J Virol (2005) 0.92
Roles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactions. Cell Res (2005) 0.91
Vdelta2 T-lymphocyte responses in cord blood samples from Italy and Côte d'Ivoire. Immunology (2008) 0.89
Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells. Clin Dev Immunol (2010) 0.89
Lymphocytic choriomeningitis virus (LCMV) infection of macaques: a model for Lassa fever. Antiviral Res (2011) 0.88
Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever. J Med Virol (2004) 0.88
V gamma 9V delta 2 T-cell anergy and complementarity-determining region 3-specific depletion during paroxysm of nonendemic malaria infection. Infect Immun (2003) 0.86
Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Cytotherapy (2011) 0.86
An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J (2013) 0.86
Toxicity of trans-nonachlor to Sprague-Dawley rats in a 90-day feeding study. Food Chem Toxicol (2004) 0.86
Altered cord blood gammadelta T cell repertoire in Nigeria: possible impacts of environmental factors on neonatal immunity. Mol Immunol (2008) 0.85
Circulating natural killer and gammadelta T cells decrease soon after infection of rhesus macaques with lymphocytic choriomeningitis virus. Mem Inst Oswaldo Cruz (2009) 0.85
Toxicologic and immunologic effects of perinatal exposure to the brominated diphenyl ether (BDE) mixture DE-71 in the Sprague-Dawley rat. Environ Toxicol (2011) 0.84
The effect of moving to a new hospital facility on the prevalence of methicillin-resistant Staphylococcus aureus. Am J Infect Control (2004) 0.84
Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus. Blood (2009) 0.84
The Vgamma2/Vdelta2 T-cell repertoire in Macaca fascicularis: functional responses to phosphoantigen stimulation by the Vgamma2/Jgamma1.2 subset. Immunology (2005) 0.83
The γδ T-cell receptor repertoire is reconstituted in HIV patients after prolonged antiretroviral therapy. AIDS (2013) 0.83
Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein. J Virol (2004) 0.82
Differentiation of monocytes into CD1a- dendritic cells correlates with disease progression in HIV-infected patients. J Acquir Immune Defic Syndr (2007) 0.82
Modulating effects of dietary fats on methylmercury toxicity and distribution in rats. Toxicology (2006) 0.81
Critical roles for Akt kinase in controlling HIV envelope-mediated depletion of CD4 T cells. Retrovirology (2013) 0.81
Innate-like gammadelta T cell responses to mycobacterium Bacille Calmette-Guerin using the public V gamma 2 repertoire in Macaca fascicularis. Tuberculosis (Edinb) (2007) 0.81
Vγ2Vδ2 T cell Costimulation Increases NK cell Killing of Monocyte-derived Dendritic Cells. Immunology (2014) 0.81
Brucellosis. N Engl J Med (2005) 0.80
Immunomodulatory effects of dietary potassium perfluorooctane sulfonate (PFOS) exposure in adult Sprague-Dawley rats. J Toxicol Environ Health A (2008) 0.80
Cord blood Vγ2Vδ2 T cells provide a molecular marker for the influence of pregnancy-associated malaria on neonatal immunity. J Infect Dis (2013) 0.80
Targeting of the purine biosynthesis host cell pathway enhances the activity of tenofovir against sensitive and drug-resistant HIV-1. J Infect Dis (2013) 0.80
Effects of 15-deoxy-delta12,14-prostaglandin J2 (15d-PGJ2) and rosiglitazone on human gammadelta2 T cells. PLoS One (2009) 0.79
The α4β7 integrin binds HIV envelope but does not mediate bystander killing of γδ T cells. Blood (2012) 0.79
Human cord blood γδ T cells expressing public Vγ2 chains dominate the response to bisphosphonate plus interleukin-15. Immunology (2013) 0.79
Effects of virus burden and chemokine expression on immunity to SHIV in nonhuman primates. Viral Immunol (2004) 0.78
Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population. AIDS Patient Care STDS (2007) 0.78
CD25(+) Bcl6(low) T follicular helper cells provide help to maturing B cells in germinal centers of human tonsil. Eur J Immunol (2014) 0.78
Effects of long term exposure to the mycotoxin fumonisin B1 in p53 heterozygous and p53 homozygous transgenic mice. Food Chem Toxicol (2012) 0.77
Enantioselective and gender-dependent depletion of chlordane compounds from rat tissues. J Toxicol Environ Health A (2005) 0.77
Toxicity of the chlordane metabolite oxychlordane in female rats: clinical and histopathological changes. Food Chem Toxicol (2003) 0.77
Simian/human immunodeficiency virus(89.6) expressing the chemokine genes MIP-1alpha, RANTES, or lymphotactin. Viral Immunol (2003) 0.76
Reply to Hartjen et al. J Infect Dis (2013) 0.75
A plea for justice for jailed medical workers. Science (2006) 0.75
Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine. HIV Clin Trials (2009) 0.75
A prickly situation. Am J Med (2008) 0.75